Heghine Khachatryan: What EHA 2026 Reveals About the Future of Aplastic Anemia Treatment
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared American Society of Hematology’s post on LinkedIn:
“Aplastic Anemia in 2026: Moving Beyond Traditional IST
The management of severe aplastic anemia continues to evolve.
While horse ATG plus cyclosporine remains the backbone of frontline immunosuppressive therapy, recent studies and EHA 2026 discussions highlight the growing role of thrombopoietin receptor agonists (especially eltrombopag) in improving hematologic responses and reducing transfusion dependence.
Key trends shaping 2026 practice include:
- Earlier integration of TPO-receptor agonists into frontline therapy
- Improved risk stratification through molecular profiling and clonal evolution monitoring
- More individualized treatment selection based on age, donor availability, and genomic findings
- Ongoing refinement of the balance between immunosuppression and stem cell transplantation strategies
The future of aplastic anemia treatment is increasingly focused on precision medicine, deeper responses, and long-term prevention of clonal progression.”
American Society of Hematology shared a post on LinkedIn:
“How is frontline immunosuppressive therapy for aplastic anemia evolving in 2026?
Join the next Aplastic Anemia Clinical Case Webinar focusing on highlights from EHA 2026 and practical, evidence-based strategies for patient management.
June 18 | 6–7 p.m.
Register now.”
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?